Evidence map›Paper›PMID 35462149›Full record

ArticleInternational journal of surgery case reports2022

Curative remnant total pancreatectomy for recurrent pancreatic acinar cell carcinoma: A case report.

Masahide Hiyoshi, Kengo Kai, Takeomi Hamada, Koichi Yano, Naoya Imamura, Atsushi Nanashima

Open access · goldAbstract read
In one paragraph

Article in International journal of surgery case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Masahide HiyoshiDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, University of Miyazaki, Faculty of Medicine, Miyazaki, Japan. Electronic address: mhiyoshi@med.miyazaki-u.ac.jp.
Kengo KaiDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, University of Miyazaki, Faculty of Medicine, Miyazaki, Japan.
Takeomi HamadaDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, University of Miyazaki, Faculty of Medicine, Miyazaki, Japan.
Koichi YanoDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, University of Miyazaki, Faculty of Medicine, Miyazaki, Japan.
Naoya ImamuraDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, University of Miyazaki, Faculty of Medicine, Miyazaki, Japan.
Atsushi NanashimaDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, University of Miyazaki, Faculty of Medicine, Miyazaki, Japan.
University of Miyazaki · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and importanceAcinar cell carcinoma (ACC) of the pancreas is a rare pancreatic cancer subtype (incidence, 0.5-2%) with unclear epidemiology and prognosis. Sometimes, repeat resection including total pancreatectomy is required for recurrence. We report a case of ACC recurring in the remnant pancreatic head after distal pancreatectomy that was successfully cured by remnant pancreatic resection following combination therapy with nab-paclitaxel (nab-PTX) and gemcitabine (GEM). CASE PRESENTATION: A 64-year-old woman was referred for pancreatic tumour treatment. CT revealed a 46-mm tumour in the pancreatic body, and endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) indicated ACC. Distal pancreatectomy was performed, and the final diagnosis was ACC. CT 18 months later showed a 34-mm tumour in the remnant pancreatic head revealed as ACC by EUS-FNA. Portal vein invasion was apparent, so neoadjuvant chemotherapy with nab-PTX and GEM was administered, and remnant pancreatic resection (total pancreatectomy) was performed. No recurrence or distant metastasis was present more than 6 months later. CLINICAL DISCUSSION: Mean survival time for ACC is 18-47 months, and prognosis is good compared with pancreatic ductal adenocarcinoma (PDAC). ACC tends to extend and grow along the main pancreatic duct, which increases the recurrence rate to 50-60%. EUS and EUS-FNA were useful for evaluating tumour extension and diagnosis. Repeat pancreatic resection that included total pancreatectomy was feasible and could be performed safely.

conclusionACC has a better prognosis than PDAC but with a higher recurrence rate. Aggressive surgical resection that included remnant total pancreatotomy with chemotherapy was useful in treating ACC.

Indexed as

Case reportNeoadjuvant chemotherapyPancreatic acinar cell carcinomaRecurrenceTotal pancreatectomy

Identifiers

PMID35462149
PMCPMC9046634
OpenAlexW4224310593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.